Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes.

Diabetes mellitus, particularly Type 2 diabetes (T2DM) remains a significant concern globally with an increase in prevalence reported in recent years. If diabetes is not managed properly, it can lead to several complications including an increased risk of cardiovascular disease (CVD). Cardiovascular complications such as coronary heart disease, peripheral artery disease, and stroke are common among individuals with diabetes. Therefore, the timely management of diabetes becomes very important. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a promising class of medications that offer benefits beyond glycemic control. Among various benefits, GLP-1 RAs can promote pancreatic β-cell proliferation and reduce their apoptosis. They also exert central effects on appetite and energy balance. Furthermore, the weight-lowering potential of GLP-1 RAs has also been documented in literature which can provide indirect benefit to CVD prevention. Long-term GLP-1 RAs generally have superior efficacy over short-term GLP-1 RAs in terms of controlling overnight and fasting plasma glucose levels. However, short-acting GLP-1 RAs, such as exenatide and lixisenatide, maintain their influence on gastric emptying during prolonged use. Adverse events, particularly, gastrointestinal adverse events, remain a concern with GLP-1 RA use. These symptoms usually appear at the start of treatment but fade as the body adjusts to the medication. GLP-1 RAs have shown beneficial effects on cardiovascular health, including a reduction in the incidence of major adverse cardiovascular events. In conclusion, GLP-1 RAs provide multifaceted benefits in T2DM as they not only maintain glycemic control but also decrease cardiovascular risk.